| Autor: |
Wijayanegara, H, Mose, JC, Achmad, L, Sobarna, R, Permadi, W |
| Zdroj: |
Journal of International Medical Research; February 1992, Vol. 20 Issue: 1 p54-60, 7p |
| Abstrakt: |
The safety and efficacy of 500 mg O-(β-hydroxyethyl)rutosides given orally twice daily in the treatment of 97 patients with first-, second-, or third-degree haemorrhoids were investigated in a double-blind, randomized placebo-controlled trial. The rutosides produced a significant (P< 0.001) improvement in patient-assessed subjective symptoms (pain, bleeding, exudation and pruritus) compared with placebo. There was also a significant (P< 0.0001) improvement in clinician-assessed subjective and objective signs (bleeding, inflammation and dilatation of the haemorrhoidal plexus) after 2 and 4 weeks' treatment compared with placebo. There were three mild, transient side-effects reported in the active treatment group and no drug-related problems in the pregnancy or delivery were observed. The results suggest that O-(β-hydroxyethyl)rutosides provide a safe and effective treatment for women with haemorrhoids of pregnancy. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
